Biotech Firm Ceragon Reports Strong Financial Performance in Q4 2025

Ceragon Pharmaceuticals Inc., the biopharmaceutical company focused on developing and commercializing novel treatments for cancer, reported a strong Q4 2025 earnings call, driven by increased revenue from its lead product candidate. The company’s top-line revenue for the quarter was $43.7 million, exceeding market expectations, with sales of its lead product candidate, ZAROSUXIMAB-DMW, reaching $30.2 million. This represents a significant increase over Q4 2024, when the company reported revenue of $24.5 million. Gross margin for the quarter was 86%, with operating expenses decreasing by 10% year-over-year to $34.8 million, resulting in net income of $6.3 million. CEO Paul Mason attributed the strong financial performance to the increasing adoption of ZAROSUXIMAB-DMW by major hospitals and research institutions worldwide. The company’s commercial team reported that several key accounts have begun stocking the product, leading to a surge in demand. “We are seeing significant traction with our lead product candidate, and it’s clear that the market is recognizing its value,” Mason said. “Our commercial team has worked tirelessly to build strong relationships with our customers, and we’re confident that this momentum will continue into 2026 and beyond.” Looking ahead, Ceragon reaffirmed its guidance for full-year 2026 revenue of $120 million, driven by continued growth in sales of ZAROSUXIMAB-DMW. The company expects to expand its commercial team and invest in marketing efforts to further increase brand awareness. In the Q4 2025 earnings call, Ceragon also announced that it has received positive results from a phase II clinical trial evaluating ZAROSUXIMAB-DMW for the treatment of solid tumors with PD-L1 expression. The company plans to present these results at an upcoming medical conference and expects to submit a new IND application later in 2026. With its strong Q4 performance and promising pipeline, Ceragon is well-positioned for continued growth and success in the coming years.